Ginko biloba, áno, či nie? Všetky zdroje
ZDROJE (Alzheimer)
1. Dmasio
AR. Alzheimer’s disease and related dementias. In: Bennett CJ, Plum F, eds. Cecil
textbook of medicine. 20th edn. Philadelphia, PA: WB Saunders. 1996: p 1992–1996
2. Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radical Biol Med 1997;
23: 134–147
3. Shin RW. Interaction of aluminum with paired helical filament tau is involved in neurofibrially
pathology of Alzheimer’s disease. Gerontol 1997; 43(suppl 1): 16–23
4. Zapatero MD, Garcia de Jalon A, Pascual F et al. Serum aluminum levels in Alzheimer’s disease
and other senile dementias. Biol Trace Element Res 1995; 47: 235–240
5. Frolich L, Riederer, P. Free radical mechanisms in dementia of the Alzheimer’s type and the
potential for antioxidative treatment. Drug Res 1995; 45: 443–446
6. Walton J et al. Uptake of trace amounts of aluminum into the brain from drinking water.
Neurotoxicology 1995; 16: 187–190
7. Garcia CA, Reding MJ, Blass JP. Over diagnosis of dementia. J Am Ger Soc 1981; 29: 407–410
8. Smith JS, Kiloh LG. The investigation of dementia. Results in 200 consecutive admissions. Lancet
1981; 1: 824–827
9. Weinreb HJ. Fingerprint patterns in Alzheimer’s disease. Arch Neurol 1985; 42: 50–54
10. Kuller LH. Hormone replacement therapy and its potential relationship to dementia. JAGS 1996;
44: 878–880
11. Paganini-Hill A. Oestrogen replacement therapy and Alzheimer’s disease. Br J Obstet Gyn 1996;
103(suppl 13): 80–86
12. Honjo H, Tanaka K, Kashiwagi T et al. Senile dementia – Alzheimer’s type and estrogen. Horm
Metab Res 1995; 27: 204–207
13. Smalheiser NR, Swansom DR. lisking estrogen to Alzheimer’s disease. An informatics approach.
Neurology 1996; 47: 809–810
14. Matthews KA, Kuller LH, Wing RR et al. Prior to use of estrogen replacement therapy, are uses
healthier than nonusers? Am J Epidemiol 1996; 143: 971–978
15. Nolan CR, CeGoes JJ, Alfrey AC et al. Aluminum and lead absorption from dietary sources in
women ingesting calcium citrate. Southern Med J 1994; 87: 894–898
16. Glick JL. Dementias. The role of magnesium deficiency and hypothesis concerning the
pathogenesis of Alzheimer’s disease. Med Hypoth 1990; 31: 211–225
17. Tucker DM, Penland JG, Sandstead HH et al. Nutrition status and brain function in aging. Am J
Clin Nutr 1990; 52: 93–102
18. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of
aging. Proc Natl Acad Sci 1993; 90: 7915–7922
19. Smith MA, Perry G, Richey PL et al. Oxidative damage in Alzheimer’s disease. Nature 1996; 382:
120–121
20. Jama JW, Launer LJ, Witteman JC et al. Dietary antioxidants and cognitive function in a
population-based sample of older persons. Am J Epidem 1996; 144: 275–280
21. Evans DA and Morris MC. Is a randomized trial of antioxidants in the primary prevention of
Alzheimer disease warranted. Alzheimer Dis Assoc Disorders 1996; 10(suppl 1): 45–49
22. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease. Ann
Neurol 1992; 32: S128–132
23. Spagnoli A et al. Long-term acetyl-L-carnitine treatment in Alzheimer’s disease. Neurology 1991;
41: 1726–1732
ZDROJE (Ginko biloba)
1. DeFeudis
FV, ed. Ginkgo biloba Extract (EGb 761). Pharmacological activities and clinical
applications. Elsevier: Paris. 1991
2. EW Funfgeld, ed. Rokan (Ginkgo biloba). Recent results in pharmacology and clinic. New York:
Springer-Verlag, 1988
3. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992; 340: 1136–1139
4. Kleijnen
J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clinical Pharmacol @ 34:
352–8, 1992
5. Schaffler VK, Reeh PW. Double-blind study of the hypoxia-protective effect of a standardized
Ginkgo bilobae preparation after repeated administration in healthy volunteers. Arzneim-Forsch 1985;
35: 1283–1286
6. Chatterjee SS, Gabard B. Studies on the mechanism of action of an extract of Ginkgo biloba, a drug
for the treatment of ischemic vascular diseases. Naunyn-Schmiedeberg‘s Arch Pharmacol 1982;
320: R52
7. Le Poncin, Lafitte M, Rapin J et al. Effect of Ginkgo biloba on changes induced by quantitative
cerebral microembolization in rats. Archs Int Pharmacodyn Ther 1980; 243: 236–244
8. Karcher L, Zagerman P, Krieglstein J. Effect of an extract of Ginkgo biloba on rat brain energy
metabolism in hypoxia. Naunyn-Schmiedeberg‘s Arch Pharmacol 1984; 327: 31–35
9. Schmidt U, Rabinovici K, Lande S. Einfluss eines Ginkgo biloba specialextraktes auf doe
befomdlickeit bei zerebraler onsufficizienz. Munch Med Wockenschr 1991; 133: S15–18
10. Bruchert E, Heinrich SE, Ruf-Kohler P. Wirksamkeit von LI 1370 bei alteren patienten mit
himleistungsschwache. Multizentrische doppelblindstudie des fachverbandes Deutscher
Allegemeinaezte.
Munch Med Wockenschr 1991; 133: S9–14
11. Meyer B. Etude multicentrique randomisee a double insu face au placebo due traitment des
acouphenes par l‘extrait de Gingko biloba. Presse Med 1986; 15: 1562–1564
12. Taillandier J et al. Traitment des troubles du vidillissement cerebral pal l‘extrait Ginkgo biloba.
Presse Med 1986; 15: 1583–1587
13. Koltai M, Hosford D, Guinot P et al. Platelet activating factor (PAF). A review of its effects,
antagonists and possible future clinical implications (Part I). Drugs 1991; 42: 9–29
14. Koltai M et al. PAF. A review of its effects, antagonists and possible future clinical implications
(Part II). Drugs 1991; 42: 174–204
15. Haguenauer JP, Canteno F, Koskas H et al. Traitment des troubles de l‘equilibre par l‘extrai
Ginkgo biloba. Press Med 1986; 15: 1569–1572
16. Vorberg G, Schmidt U, Schenk N. Wirksamkeit eines neuen Ginkgo biloba extraktes bei 100
patienten mit zerebraler insuffizienz. Herg + Gefasse 1989; 9: 936–941
17. Eckmann F. Himleistungsstorungen – behandlung mit Ginkgo biloba extrakt. Fortsch Med 1990;
108: 557–560
18. Wesnes K et al. A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic
cognitive impairment in the elderly. Hum Psychopharmacol 1987; 2: 159–169
19. Anadere I, Chmiel H, Witte S. Hemorrheological findings in patients with completed stroke and the
influence of Ginkgo biloba extract. Clin Hemorheo 1985; 4: 411–420
20. Gessner B, Voelp A, Klasser M. Study of the long-term action of a Ginkgo biloba extract on
vigilance and mental performance as determined by means of quantitative pharmaco-EEG and
psychometric measurements. Arzneim Forsch 1985; 35: 1459–1465
21. Hofferberth B. Effect of Ginkgo biloba extract on neurophysiological and psychometric
measurement in patients with cerebro-organic syndrome – A double-blind study versus placebo.
Arzneim
Forsch 1989; 39: 918–922
22. Hindmarch I, Subhan Z. The psychopharmacological effects of Ginkgo biloba extract in normal
healthy volunteers. Int J Clin Pharmacol Res 1984; 4: 89–93
23. Hofferberth B. The efficacy of Egb761 in patients with senile dementia of the Alzheimer type. A
double-blind, placebo-controlled study on different levels of investigation. Human Psychopharmacol
1994; 9: 215–222
24. Meyer B. A multicenter randomized double-blind study of Ginkgo biloba extract versus placebo in
the treatment of tinnitus. In: Funfgeld EW, ed. Rokan ( Ginkgo biloba) – recent results in
pharmacology and clinic. New York, NY: Springer-Verlag. 1988: p 245–250
25. Coles RRA. Trial of an extract of Ginkgo biloba (EGB) for tinnitus and hearing loss. Clin
Otolaryngol 1988; 13: 501–504
26. Holgers KM, Axelsson A, Pringle I. Ginkgo biloba extract for the treatment of tinnitus. Audiology
1994; 33: 85–92
27. Bascher V, Steinert W. Differential diagnosis of sudden deafness and therapy with high dose
infusions of Ginkgo biloba extract. In: Clausen CF, Kirtane MV, Schlitter K, eds. Vertigo, nausea,
tinnitus, and hypoacusia in metabolic disorders. Amsterdam: Elsevier. 1988: p 575–582
28. Lanthony P, Cosson JP. Evolution de la vision des couleurs dans la retinopathie diabetique
debutante traitee par extait de Ginkgo biloba. J Fr Ophtalmol 1988; 11: 671–674
29. De
Felice M, Gallo P, Masotti G. Current therapy of peripheral obstructive arterial disease. The
non-surgical approach. Angiology 1990; 41: 1–11
30. Ernst E. Pentoxifylline for intermittent claudication. A critical review. Angiology 1994; 45: 339–345
31. Schneider B. Ginkgo biloba extract in peripheral arterial diseases. Meta-analysis of controlled
clinical studies. Arzneim Forsch 1992; 42: 428–436
32. Thomson GJ, Vohra RK, Carr MH et al. A clinical trial of Gingko biloba extract in patients with
intermittent claudication. Int Angiol 1990; 9: 75–78
33. Saudreau F, Serise JM, Pillet J et al. Efficacy of Ginkgo biloba extract in the treatment of lower
limb obliterative artery disease at stage III of the Fontaine classification. J Mal Vasc 1989; 14:
177–182
34. Rudofsky VG. The effect of Ginkgo biloba extract in cases of arterial occlusive disease. A
randomized placebo controlled double-blind cross-over study. Fortschr Med 1987; 105: 397–400
35. Bauer U. Ginkgo biloba extract in the treatment of arteriopathy of the lower limbs. Sixty-five week
study. Presse Médicale 1986; 15: 1546–1549
36. Bauer U. 6-month double-blind randomized clinical trial of Ginkgo biloba extract versus placebo in
two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneim Forsch
1984; 34: 716–721
37. Sikora R, Sohn M, Deutz FJ et al. Ginkgo biloba extract in the therapy of erectile dysfunction.
Journal of Urology 1989; 141: 188A
38. Tamborini A, Taurelle R. Value of standardized Ginkgo biloba extract (Egb 761) in the
management of congestive symptoms of premenstrual syndrome. Rev Fr Gynecol Obstet 1993; 88:
447–457
39. Schubert H, Halama P. Depressive episode primarily unresponsive to therapy in elderly patients.
Efficacy of Ginkgo biloba (Egb 761) in combination with antidepressants. Geriatr Forsch 1993; 3:
45–53
40. Becker LE, Skipworth GB. Ginkgo-tree dermatitis, stomatitis, and proctitis. JAMA 1975; 231: 1162–
1163